trovafloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, nalidixic acid derivatives 2777 147059-72-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trovafloxacin
  • trovafloxacin mesylate
  • trovafloxacin mesilate
  • trovafloxacin acid
a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity
  • Molecular weight: 416.36
  • Formula: C20H15F3N4O3
  • CLOGP: -1.47
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 99.76
  • ALOGS: -3.77
  • ROTB: 3

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O
0.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 91 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.24 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 11 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 18, 1997 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01MA13 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
QUINOLONE ANTIBACTERIALS
Fluoroquinolones
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D059005 Topoisomerase II Inhibitors
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:50908 agente hepatotoxico
CHEBI has role CHEBI:53559 topoisomerase IV inhibitors
CHEBI has role CHEBI:59517 DNA synthesis inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Infection due to Pseudomonas aeruginosa indication 11218009
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Acute gonococcal urethritis indication 29864006
Acute bacterial peritonitis indication 31860008
Postoperative infection indication 33910007
Pneumonia due to Streptococcus indication 34020007
Pneumonia due to Pseudomonas indication 41381004
Gonorrhea of rectum indication 42746002
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Pneumonia due to Escherichia coli indication 51530003
Acute gonococcal endometritis indication 65295003 DOID:7527
Miscarriage with sepsis indication 67465009
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Acute bacterial sinusitis indication 75498004
Endomyometritis indication 88027004
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Postnatal infection indication 178280004
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Chlamydial pelvic inflammatory disease indication 188463006
Acute Moraxella catarrhalis bronchitis indication 195722003
Acute bacterial bronchitis indication 233598009
Chlamydial pneumonia indication 233609002
Female pelvic cellulitis indication 280486004
Streptococcal Septic Abortion indication
Complicated Klebsiella Peritonitis indication
Complicated E. Coli Peritonitis indication
Enterococcus Endomyometritis indication
Complicated Streptococcus Peritonitis indication
Complicated Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Complicated Bacteroides Peritonitis indication
Prevotella Postpartum Infection indication
Gardnerella Endomyometritis indication
Bacteroides Septic Abortion indication
Gardnerella Postpartum Infection indication
Peptostreptococcus Pelvic Cellulitis indication
Prevotella Septic Abortion indication
E. Coli Endomyometritis indication
Colorectal Surgery Infection Prevention indication
Vaginal Hysterectomy Infection Prevention indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea indication
Chronic Bacterial Prostatitis indication
Haemophilus Parainfluenzae Bronchitis indication
Haemophilus Influenzae Bronchitis indication
Streptococcus Pneumoniae Bronchitis indication
Staphylococcus Aureus Bronchitis indication
Chlamydia Cervicitis indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection indication
Moraxella Catarrhalis Pneumonia indication
Streptococcal Endomyometritis indication
Peptostreptococcus Postpartum Infection indication
Legionella Pneumophila Pneumonia indication
Peptostreptococcus Septic Abortion indication
Streptococcal Postpartum Infection indication
E. Coli Pelvic Cellulitis indication
E. Coli Postpartum Infection indication
Enterococcus Postpartum Infection indication
E. Coli Septic Abortion indication
Peptostreptococcus Endomyometritis indication
Gardnerella Septic Abortion indication
Prevotella Endomyometritis indication
Complicated Bacterial Peritonitis indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Prevotella Pelvic Cellulitis indication
Streptococcal Pelvic Cellulitis indication
Bacteroides Postpartum Infection indication
Gardnerella Pelvic Cellulitis indication
Enterococcus Pelvic Cellulitis indication
Complicated Skin and Skin Structure Proteus Infection indication
Enterococcus Septic Abortion indication
Complicated Skin and Skin Structure E. Coli Infection indication
Bacteroides Pelvic Cellulitis indication
Bacteroides Endomyometritis indication
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.92 acidic
pKa2 8.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter Ki 4.31 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 5.40 DRUG MATRIX
Topoisomerase IV Enzyme INHIBITOR CHEMBL CHEMBL
DNA gyrase Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4024108 VUID
N0000022113 NUI
D02123 KEGG_DRUG
147059-75-4 SECONDARY_CAS_RN
4021091 VANDF
4024108 VANDF
C0379881 UMLSCUI
CHEBI:9763 CHEBI
TR6 PDB_CHEM_ID
CHEMBL428 ChEMBL_ID
CHEMBL1200779 ChEMBL_ID
DB00685 DRUGBANK_ID
C080163 MESH_SUPPLEMENTAL_RECORD_UI
62959 PUBCHEM_CID
7370 INN_ID
9F388J00UK UNII
115552 RXNORM
5646 MMSL
7888 MMSL
d04263 MMSL
007320 NDDF
007321 NDDF
116542007 SNOMEDCT_US
371322001 SNOMEDCT_US
96092008 SNOMEDCT_US

Pharmaceutical products:

None